CinnaGen Co. announced that the results of preliminary analysis of data from the ongoing Phase 2 human clinical trial of SpikoGen vaccine based on Vaxine’s COVID-19 vaccine technology were positive.

This vaccine comprises a recombinant spike protein antigen formulated with the proprietary Advax-SM adjuvant.

The Phase 2 study was a randomized, double-blind, placebo-controlled trial conducted on 400 volunteers assigned to receive two doses, 21 days apart of  active vaccine or saline placebo in a 3:1 ratio.

According to CinnaGen, their vaccine branded as SpikoGen was well tolerated in all participants and showed a promising immunogenicity profile. With positive data from this ongoing Phase 2 study CinnaGen now plans to start a large Phase III clinical trial.